Skip to main content

Table 1 Patients clinical characteristics by furosemide users and non-users

From: Furosemide use and survival in patients with esophageal or gastric cancer: a population-based cohort study

  Esophageal n (%) Gastric n (%)
  Users Never-users Users Never-users
Year of diagnosis 1998–2002 85 (25%) 482 (20%) 116 (31%) 507 (25%)
2003–2007 123 (36%) 789 (33%) 126 (34%) 719 (36%)
2008–2013 135 (39%) 1094 (46%) 130 (35%) 779 (39%)
Age at diagnosis: mean   74.5 68.2 76.5 69.6
< 60 25 (7%) 564 (24%) 21 (6%) 408 (20%)
60–69 86 (25%) 755 (32%) 64 (17%) 506 (25%)
70–79 124 (36%) 655 (28%) 150 (40%) 698 (35%)
80+ 108 (31%) 391 (17%) 137 (37%) 393 (20%)
Gender Male 217 (63%) 1611 (68%) 241 (65%) 1368 (68%)
Deprivation quintile 1 (least deprived) 63 (18%) 501 (21%) 68 (18%) 381 (19%)
2 86 (25%) 602 (25%) 93 (25%) 480 (24%)
3 70 (20%) 469 (20%) 61 (16%) 413 (21%)
4 71 (21%) 446 (19%) 81 (22%) 429 (22%)
5 (most deprived) 53 (15%) 346 (15%) 69 (19%) 299 (15%)
Treatment Surgery 125 (36%) 959 (41%) 181 (49%) 1029 (51%)
Chemotherapy 116 (34%) 1178 (50%) 76 (20%) 784 (39%)
Radiotherapy 108 (31%) 591 (25%) 30 (8%) 130 (6%)
Tumor type Adenocarcinoma 214 (62%) 1391 (59%) 303 (81%) 1581 (79%)
Squamous 99 (29%) 716 (30%) <5a 19 (1%)
Others 30 (9%) 258 (11%) 64-69a 405 (20%)
Grade 1 17 (7%) 92 (5%) 18 (7%) 69 (5%)
2 131 (53%) 775 (44%) 103 (40%) 484 (33%)
3 93-98a 892 (50%) 132-137a 892 (61%)
4 <5a 16 (1%) <5a 17 (1%)
Missing 97 590 114 543
Stage 1 8 (17%) 36 (8%) 7 (16%) 33 (12%)
2 10 (21%) 86 (18%) 9 (21%) 54 (20%)
3 20 (43%) 208 (44%) 8 (19%) 67 (28%)
4 9 (19%) 143 (30%) 19 (44%) 116 (43%)
Missing 296 1892 329 1735
Other medication useb Statin 133 (39%) 553 (23%) 164 (44%) 479 (24%)
Aspirin 146 (43%) 423 (18%) 132 (35%) 366 (18%)
Smoking Never 101 (43%) 701 (39%) 103 (39%) 609 (42%)
Former 94 (40%) 621 (35%) 123 (46%) 510 (35%)
Current 42 (18%) 473 (26%) 39 (15%) 318 (22%)
Missing 106 570 107 568
Alcohol consumption Never 36 (16%) 235 (15%) 51 (20%) 243 (18%)
Former 7 (3%) 63 (4%) 12 (5%) 45 (3%)
Current 184 (81%) 1322 (82%) 191 (75%) 1030 (78%)
Missing 116 745 118 687
BMI Underweight (< 18.5) 6 (3%) 68 (5%) <5a 50 (4%)
Normal (18.5–24.9) 63 (29%) 549 (38%) 64-69a 429 (35%)
Overweight (25–29.9) 86 (39%) 531 (37%) 91 (39%) 504 (41%)
Obese (≥30) 63 (29%) 300 (21%) 74 (32%) 238 (19%)
Missing 125 917 138 784
Selected comorbidities Heart failure 51 (15%) 58 (2%) 64 (17%) 61 (3%)
Myocardial infarction 38 (11%) 124 (5%) 48 (13%) 115 (6%)
Hypertension 187 (55%) 979 (41%) 217 (58%) 826 (41%)
Edema 79 (23%) 185 (8%) 86 (23%) 148 (7%)
  1. aRanges presented for statistical disclosure control
  2. bAfter cancer diagnosis, using a 6 months lag (same as furosemide)
\